Genetic Landscape of Electron Transport Chain Complex I Dependency in Acute Myeloid Leukemia
Irène Baccelli, Yves Gareau, Bernhard LehnertziD, Stéphane Gingras, Jean-François SpinellaiD, Alexandre Beautrait, Sophie CorneauiD, Nadine MayotteiD, Isabel BoiviniD, Simon Girard, Tara MacRaeiD, Mélanie Frechette, Koryne Leveillé, Jana Krosl, Clarisse Thiollier, Vincent-Philippe Lavallée, Evgeny Kanshin, Thierry BertomeuiD, Jasmin Coulombe-Huntington, Corinne St-Denis, Marie-Eve Bordeleau, Geneviève BoucheriD, Philippe P. RouxiD, Sébastien LemieuxiD, Mike TyersiD, , Guy SauvageauiD
Abstract
Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy in Acute Myeloid Leukemia (AML), but patients respond heterogeneously. Through chemically interrogation of 200 sequenced specimens, we identified Mubritinib as a strong in vitro and in vivo anti-leukemic compound, acting through ubiquinone-dependent inhibition of Electron Transport Chain complex I (ETC1). ETC1 targeting showed selective toxicity against a subgroup of chemotherapy-resistant leukemias exhibiting OXPHOS hyperactivity, high expression of mitochondrial activity-related genes, and mutations affecting NPM1, FLT3 and DNMT3A. Altogether, our work thus identifies a novel ETC1 inhibitor with high clinical potential and reveals the landscape of OXPHOS dependency in AML.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia
Matthew T. Villaume, Haley Elizabeth Ramsey, … Michael Robert Savona·bioRxiv·Jul 13, 2026
- Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation
H. J. Park, M. A. Gregory, … J. DeGregori·bioRxiv·Feb 14, 2022
- Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapy
James T. Hagen, McLane M. Montgomery, … Kelsey H. Fisher‐Wellman·Science AdvancesPeer-reviewed·Apr 9, 2025
- Combinatory therapy targeting mitochondrial oxidative phosphorylation improves efficacy of IDH mutant inhibitors in acute myeloid leukemia
L. Stuani, J.-E. Sarry·bioRxiv·Aug 28, 2019
- Clever-1 blockade disrupts lipid metabolism and mitochondrial fitness in acute myeloid leukemia
Arno Ylitalo, Jesper Mickos, … Maija Hollmén·bioRxiv·Aug 12, 2026
- The EAAT1 aspartate/glutamate transporter is dispensable for acute myeloid leukemia cell growth and response to therapy
Hernán A. Tirado, Nithya Balasundaram, … Nick van Gastel·PLoS ONEPeer-reviewed·Feb 24, 2026